Updated cancer treatment framework offers new guidance on actionability and resistance biomarkers
ESMO has published version 2 of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), a major update to the internationally recognized precision oncology framework that helps oncologists assess the clinical relevance of molecular alterations and match patients with the most appropriate targeted therapies.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
